MYCN and neuroblastoma: Risk stratification, defined as the categorization of patients into low-, intermediate-, and high-risk groups, is the primary determinant of prognosis for NB and assigns patients to treatment protocols based on age at diagnosis, MYCN oncogene amplification, histology, stage of disease, and ploidy status [7,8].